Pfizer forecasts 2026 profit below expectations on lower COVID product sales

Dec 16 (Reuters) – Pfizer (PFE) on Tuesday forecast 2026 ​profit below Wall Street ‌estimates as it expects lower ‌sales of its COVID products, sending its shares down 0.4% in premarket ⁠trading.

The drugmaker ‌expects adjusted profit of between $2.80 and $3 per ‍share for the coming year, below analysts’ average estimate ​of $3.05 per share, according ‌to data compiled by LSEG.

It expects revenue for the year in the range of $59.5 billion to $62.5 ⁠billion, compared with ​estimates of $61.59 ​billion.

That includes the expectation of revenue from COVID-19 ‍products ⁠being about $1.5 billion lower than what was expected ⁠in 2025.

(Reporting by Puyaan Singh ‌in Bengaluru; Editing by ‌Anil D’Silva)